Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

Dramatic Aggregation of Alzheimer Aβ by Cu(II) Is Induced by Conditions Representing Physiological Acidosis

Atwood, C. S., Moir, R. D., Huang, X., Scarpa, R. C., Bacarra, N. M. E., Romano, D. M., Hartshorn, M. A., Tanzi, R. E., & Bush, A. I. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.21.12817 · Cited by 1,009 · see citing works

Cerebrospinal Fluid β-Amyloid(1-42) in Alzheimer Disease: Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (1999) · Archives of Neurology · doi:10.1001/archneur.56.6.673 · Cited by 660 · see citing works

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works

Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay

Ida, N., Hartmann, T., Pantel, J., Schrüder, J., Zerfaß, R., Fürstl, H., Sandbrink, R., Masters, C. L., & Beyreuther, K. T. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22908 · Cited by 476 · see citing works

Cerebrospinal fluid protein biomarkers for Alzheimer’s disease

Blennow, K. (2004) · Neurotherapeutics · doi:10.1602/neurorx.1.2.213 · Cited by 487 · see citing works

Solution structures of micelle-bound amyloid β-(1-40) and β-(1-42) peptides of Alzheimer’s disease 1 1Edited by P. E. Wright

Shao, H., Jao, S., Ma, K., & Zagorski, M. G. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.2348 · Cited by 308 · see citing works

Standardization of measurement of β-amyloid_(1-42)in cerebrospinal fluid and plasma

Vanderstichele, H., Kerschaver, E. V., Hesse, C., Davidsson, P., Buyse, M.-A., Andreasen, N., Minthon, L., Wallin, A., Blennow, K., & Vanmechelen, E. (2000) · Amyloid · doi:10.3109/13506120009146438 · Cited by 301 · see citing works

The Profile of Soluble Amyloid β Protein in Cultured Cell Media

Wang, R., Sweeney, D. A., Gandy, S., & Sisodia, S. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31894 · Cited by 293 · see citing works

Highly conserved and disease‐specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer's disease and in patients with chronic neuroinflammation

Wiltfang, J., Esselmann, H., Bibl, M., Av, S., Otto, M., Paul, S., Schmidt, B., Klafki, H., Maler, M., Dyrks, T., et al. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00818.x · Cited by 268 · see citing works

Nicotine Inhibits Amyloid Formation by the β-Peptide

Salomon, A. R., Marcinowski, K. J., Friedland, R. P., & Zagorski, M. G. (1996) · Biochemistry · doi:10.1021/bi9617264 · Cited by 220 · see citing works

Biomarkers of Alzheimer's disease

Craig‐Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217 · see citing works

Untitled work

(1999) · doi:10.1002/1531-8249(199904)45:4

Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study

Bermejo‐Pareja, F., Antequera, D., Vargas, T., Molina, J. A., & Carro, E. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-108 · Cited by 192 · see citing works

[13] Methodological and chemical factors affecting amyloid β peptide amyloidogenicity

Zagorski, M. G., Yang, J., Shao, H., Ma, K., Zeng, H., & Hong, A. (1999) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(99)09015-1 · Cited by 185 · see citing works

Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease

Gasparini, L., Racchi, M., Binetti, G. G., Trabucchi, M., Solerte, S. B., Alkon, D. L., Etcheberrigaray, R., Gibson, G. E., Blass, J. P., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 175 · see citing works

Effects of Processing and Storage Conditions on Amyloid β (1–42) and Tau Concentrations in Cerebrospinal Fluid: Implications for Use in Clinical Practice

Schoonenboom, N. S. M., Mulder, C., Vanderstichele, H., van Elk, E.-J., Kok, A., van Kamp, G. J., Scheltens, P., & Blankenstein, M. A. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2004.039735 · Cited by 165 · see citing works

CSF biomarkers for mild cognitive impairment

Blennow, K. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01368.x · Cited by 151 · see citing works

Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients

Fukuyama, R., Mizuno, T., Mizuno, T., Mori, S., Nakajima, K., Fushiki, S., & Yanagisawa, K. (2000) · European Neurology · doi:10.1159/000008156 · Cited by 112 · see citing works

Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β-peptide

Jao, S., Ma, K., Talafous, J., Orlando, R., & Zagorski, M. G. (1997) · Amyloid · doi:10.3109/13506129709003835 · Cited by 107 · see citing works

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease

Alawode, D. O. T., Heslegrave, A., Ashton, N. J., Karikari, T. K., Simrén, J., Montoliu‐Gaya, L., Pannee, J., O’Connor, A., Weston, P. S. J., Lantero‐Rodriguez, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13332 · Cited by 100 · see citing works

Competitive electrochemical immunoassay for detection of β-amyloid (1–42) and total β-amyloid peptides using p-aminophenol redox cycling

Liu, L., He, Q., Zhao, F., et al. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.07.047 · Cited by 96 · see citing works

Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease

Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 92 · see citing works

β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease

Andreasen, N., & Blennow, K. (2002) · Peptides · doi:10.1016/s0196-9781(02)00056-6 · Cited by 83 · see citing works

Solution Structure Model of Residues 1−28 of the Amyloid β-Peptide When Bound to Micelles

Marcinowski, K. J., Shao, H., Clancy, E. L., & Zagorski, M. G. (1998) · Journal of the American Chemical Society · doi:10.1021/ja9738687 · Cited by 81 · see citing works

Cerebrospinal Fluid Levels of Amyloid Precursor Protein and Amyloid β-Peptide in Alzheimer’s Disease and Major Depression – Inverse Correlation with Dementia Severity

Höck, C., Golombowski, S., Müller-Spahn, F., Naser, W. L., Beyreuther, K. T., Mönning, U., Schenk, D., Vigo‐Pelfrey, C., Bush, A. M., Moir, R. D., et al. (1998) · European Neurology · doi:10.1159/000007917 · Cited by 80 · see citing works

Femtomole Immunodetection of Synthetic and Endogenous Amyloid-β Oligomers and Its Application to Alzheimer's Disease Drug Candidate Screening

Chang, L., Bakhos, L., Wang, Z., Venton, D. L., & Klein, W. L. (2003) · Journal of Molecular Neuroscience · doi:10.1385/jmn:20:3:305 · Cited by 79 · see citing works

The 28‐amino acid form of an APLP1‐derived Aβ‐like peptide is a surrogate marker for Aβ42 production in the central nervous system

Yanagida, K., Okochi, M., Tagami, S., Nakayama, T., Kodama, T. S., Nishitomi, K., Jiang, J., Mori, K., Tatsumi, S., Arai, T., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900026 · Cited by 78 · see citing works

Electrochemical detection of β-amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O2 reduction by Aβ(1–16)-heme-modified gold nanoparticles

Liu, L., Zhao, F., Ma, F., et al. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.05.028 · Cited by 75 · see citing works

Quantification of Alzheimer Amyloid β Peptides Ending at Residues 40 and 42 by Novel ELISA Systems

Jensen, M., Hartmann, T., Engvall, B., Wang, R., Uljon, S., Sennvik, K., Näslund, J., Muehlhauser, F., Nordstedt, C., Beyreuther, K. T., et al. (2000) · Molecular Medicine · doi:10.1007/bf03401938 · Cited by 70 · see citing works

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer’s disease

Samuels, S., Silverman, J. M., Marin, D. B., Peskind, E. R., Younki, S. G., Greenberg, D. A., Schnur, E., Santoro, J., & Davis, K. L. (1999) · Neurology · doi:10.1212/wnl.52.3.547 · Cited by 67 · see citing works

Reduced cerebrospinal fluid levels of α-secretase-cleaved amyloid precursor protein in aged rats: correlation with spatial memory deficits

Anderson, J. J., Höltz, G., Baskin, P. P., Wang, R., Mazzarelli, L., Wagner, S. L., & Menzaghi, F. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00244-4 · Cited by 62 · see citing works

Pre-analytical factors influencing the stability of cerebrospinal fluid proteins

Simonsen, A. H., Bahl, J. M. C., Danborg, P. B., Lindström, V., Larsen, S. O., GRUBB, A. O., Heegaard, N. H. H., & Waldemar, G. (2013) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2013.03.011 · Cited by 60 · see citing works

Cerebrospinal fluid Ab40 and Ab42 natural course and clinical usefulness

Shoji, M. (2002) · Frontiers in bioscience · doi:10.2741/a826 · Cited by 57 · see citing works

Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta‐peptide 25–35

Shen, Y., Xu, S., Wei, W., Wang, X., Wang, H., & Sun, X. (2002) · Journal of Pineal Research · doi:10.1034/j.1600-079x.2002.1o839.x · Cited by 57 · see citing works

Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics

Zimmermann, R., Lelental, N., Ganslandt, O., Maler, J. M., Kornhuber, J., & Lewczuk, P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110212 · Cited by 56 · see citing works

Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's Disease

Hock, C., Maddalena, A. S., Heuser, I., Naber, D., Oertel, W. H., von der Kammer, H., Wienrich, M., Raschig, A., Deng, M., Growdon, J. H., et al. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06937.x · Cited by 54 · see citing works

CSF tau and β-amyloid as biomarkers for mild cognitive impairment

Hampel, H., & Blennow, K. (2004) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2004.6.4/hhampel · Cited by 52 · see citing works

A Kinetic Model for β-Amyloid Adsorption at the Air/Solution Interface and Its Implication to the β-Amyloid Aggregation Process

Jiang, D., Dinh, K. L., Ruthenburg, T. C., Zhang, Y., Su, L., Land, D. P., & Zhou, F. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp8085792 · Cited by 51 · see citing works

Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease

Sobów, T., Flirski, M., & Liberski, P. P. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1491 · Cited by 51 · see citing works

Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease

Inoue, K., Garner, C. O., Ackermann, B. L., Oe, T., & Blair, I. A. (2006) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.2395 · Cited by 46 · see citing works

Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease

François, M., Bull, C. F., Fenech, M. F., & Leifert, W. R. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181022094924 · Cited by 45 · see citing works

Relationships Among Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer Type

Csernansky, J. G., Miller, J. P., McKeel, D. W., & Morris, J. C. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200207000-00003 · Cited by 42 · see citing works

The effects of age, apolipoprotein E phenotype and gender on the concentration of amyloid-β (Aβ) 40, Aβ42, apolipoprotein E and transthyretin in human cerebrospinal fluid

Kunicki, S., Richardson, J., Mehta, P. D., Kim, K. S., & Zorychta, E. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00027-7 · Cited by 41 · see citing works

Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease

Omar, S. H., & Preddy, J. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030063 · Cited by 40 · see citing works

Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer’s disease

Torreilles, F., & Touchon, J. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00030-2 · Cited by 37 · see citing works

Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides

Potempska, A., Mack, K., Mehta, P. D., Kim, K. S., & Miller, D. L. (1999) · Amyloid · doi:10.3109/13506129908993283 · Cited by 35 · see citing works

Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing

Blennow, K., & Vanmechelen, E. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_20 · Cited by 34 · see citing works

Cerebrospinal fluid Aβ40 and Aβ42: Natural course and clinical usefulness

Shoji, M., & Kanai, M. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3306 · Cited by 31 · see citing works

Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease

Pirttilä, T., Koivisto, K. J., Mehta, P. D., Reinikainen, K. J., Kim, K. S., Kilkku, O., Heinonen, E. H., Soininen, H. S., Riekkinen, P. J., & Wı́sniewski, H. M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00381-4 · Cited by 31 · see citing works

Transmissibility of mouse AApoAII amyloid fibrils: inactivation by physical and chemical methods

Zhang, H., Sawashita, J., Fu, X., Korenaga, T., Yan, J., Mori, M., & Higuchi, K. (2006) · The FASEB Journal · doi:10.1096/fj.05-4890fje · Cited by 29 · see citing works

Analytical Aspects of Molecular Alzheimer’s Disease Biomarkers

Andréasson, U., Vanmechelen, E., Shaw, L. M. J., Zetterberg, H., & Vanderstichele, H. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.44 · Cited by 26 · see citing works

Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study

Williams, J. H., Wilcock, G. K., Seeburger, J. L., Dallob, A. L., Laterza, O., Potter, W. Z., & Smith, A. D. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt64 · Cited by 26 · see citing works

Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease—From Brain Starch to Bench and Bedside

Pawlowski, M., Meuth, S., & Duning, T. (2017) · Diagnostics · doi:10.3390/diagnostics7030042 · Cited by 25 · see citing works

Cerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly

Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 23 · see citing works

Ca 2+ Interacts with Glu-22 of Aβ(1–42) and Phospholipid Bilayers to Accelerate the Aβ(1–42) Aggregation Below the Critical Micelle Concentration

Yi, X., Zhang, Y., Gong, M., Yu, X., Darabedian, N., Zheng, J., & Zhou, F. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00719 · Cited by 21 · see citing works

Supramolecular Structures of Amyloid-Related Peptides in an Ambient Water Nanofilm

Ye, M., Zhang, Y., Li, H., Xie, M., & Hu, J. (2010) · The Journal of Physical Chemistry B · doi:10.1021/jp105501x · Cited by 19 · see citing works

Biological markers of Alzheimer's disease

Mehta, P. D., & Pirttilä, T. (2002) · Drug Development Research · doi:10.1002/ddr.10063 · Cited by 18 · see citing works

Cerebrospinal fluid biomarkers of Alzheimer’s disease

Sui, X., Liu, J., & Yang, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1412-1 · Cited by 17 · see citing works

Prediction of deterioration in mild cognitive disorder in old age—neuropsychological and neurochemical parameters of dementia diseases

Reischies, F. M., & Hellweg, R. (2000) · Comprehensive Psychiatry · doi:10.1016/s0010-440x(00)80011-5 · Cited by 16 · see citing works

Activation of Neuronal Defense Mechanisms in Response to Pathogenic Factors Triggering Induction of Amyloidosis in Alzheimer's Disease

Maltsev, A. V., Santockyte, R., Bystryak, S. M., & Galzitskaya, O. V. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131562 · Cited by 14 · see citing works

Cerebrospinal fluid tau and Aβ42 concentrations in healthy subjects: delineation of reference intervals and their limitations

Burkhard, P. R., Fournier, R., Mermillod, B., Krause, K., Bouras, C., & Irminger‐Finger, I. (2004) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2004.071 · Cited by 14 · see citing works

Serum p97 levels as an aid to identifying Alzheimer's disease

Feldman, H., Gabathuler, R., Kennard, M. L., et al. (2001) · Journal of Alzheimer s Disease · doi:10.3233/jad-2001-3510 · Cited by 14 · see citing works

Biological Markers for Alzheimer's Disease

Tapiola, T. (2001) · Cited by 14 · see citing works

Humoral immune responses to peptides derived from the β-amyloid peptide C-terminal sequence

Miller, D. L., Potempska, A., & Mehta, P. D. (2007) · Amyloid · doi:10.1080/13506120601116500 · Cited by 12 · see citing works

Biological markers for the diagnosis of Alzheimer’s disease

Bancher, C., Jellinger, K. A., & Wichart, I. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_17 · Cited by 9 · see citing works

Lower levels of cerebrospinal fluid amyloid ß (Aß) in non-demented Indian controls

Subramanian, S., Sandhyarani, B., Shree, A., Murthy, K. K., Kalyani, K., Kumar, S., Pradeep, P., Noone, M. J., & Taly, A. B. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.08.018 · Cited by 7 · see citing works

Intensive protein synthesis in neurons and phosphorylation of beta-amyloid precursor protein and tau-protein are triggering factors of neuronal amyloidosis and Alzheimer's disease

Maltsev, A. V., Dovidchenko, N. V., Uteshev, V. K., Sokolik, V. V., Shtang, O. M., Yakushin, M. A., Sokolova, N. M., Surin, A. K., & Galzitskaya, O. V. (2013) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20135902144 · Cited by 7 · see citing works

Biological Markers of Alzheimer’s Disease

Hock, C. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00010-4 · Cited by 6 · see citing works

Scintigraphie cérébrale et démence à corps de Lewy

Farid, K., Volpe-Gillot, L., & Caillat-Vigneron, N. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.01.019 · Cited by 3 · see citing works

Genetic and Blood Biomarkers of Alzheimer`s Disease

Momeni, P., & Ferrari, R. (2010) · The Open Nuclear Medicine Journal · doi:10.2174/1876388x01002010012 · Cited by 4 · see citing works

Cerebral Zinc Metabolism in Alzheimer’s Disease

Atwood, C., Moir, R. D., Huang, X., Tanzi, R. E., & Bush, A. I. (1997) · Humana Press eBooks · doi:10.1007/978-1-59259-471-9_14 · Cited by 4 · see citing works

Aktuelle klinisch-neurochemische Diagnostik der Alzheimer-Krankheit/Current Clinical Neurochemical Diagnosis of Alzheimer’s Disease

Rösler, N., Wichart, I., & Jellinger, K. A. (2002) · Journal of Laboratory Medicine · doi:10.1515/labmed.2002.019 · Cited by 3 · see citing works

Demenz

Wiltfang, J., Trost, S., & Hampel, H.-J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_59 · Cited by 3 · see citing works

Complex Treatment of the Patients with Alzheimer’s Disease Using Stem Cell Preparations Including Extracted Fetal Stem Cells

Sinelnyk, A., Klunnyk, M. O., & Matiyashchuk, I. G. (2016) · Journal of Stem Cell Research & Therapy · doi:10.4172/2157-7633.1000369 · Cited by 1 · see citing works

Differences Between Early- and Late-Onset Alzheimer Disease and Stability During the Course of Disease

Andreasen, N., Hesse, C., Davidsson, P., Minthon, L., Wallin, A., Winblad, B. G., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2017) · Cited by 1 · see citing works

The Molecular Mechanism of Amyloidosis in Alzheimer’s Disease

Zagorski, M. G. (1999) · CRC Press eBooks · doi:10.1201/9780203909607.ch14 · Cited by 1 · see citing works

Some Noncommunicable Diseases of the Central Nervous System with a Possible Infectious Etiology (in Collaboration with V.A. Orlova, I.I. Mikhailova, A.A. Garbuzov, D.A. Khavkina, P.V. Chukhliaev, T.A. Ruzhentsova I. L. Naidenova, A. B. Danilov, A.V. Simonova, E.G. Filatova, I.A. Pavlovsky, O.V. Bystrova, A.M. Zatevalov, S.L. Bezrodny, T.Sh. Sadekov)

Zinserling, V. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-96260-9_20 · Cited by 1 · see citing works

The Effect of Apolipoprotein E Genotype on Biochemical Markers of Alzheimer's Disease

Schenk, D., Lieberburg, I. M., Motter, R. N., & Seubert, P. A. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32602.x · Cited by 1 · see citing works

Identification of Novel Fluid Biomarkers for Alzheimer's Disease

Craig‐Schapiro, R. (2012) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7pr7t12

The Early Diagnosis of Alzheimer's Disease

Ren, Y., Yang, W., Tang, X., Wu, F., Takahashi, S., & Wu, J. (2016) · Advances in psychology, mental health, and behavioral studies (APMHBS) book series · doi:10.4018/978-1-5225-0925-7.ch001

Amyloid beta and tau proteins in Alzheimer’s disease and Down syndrome

Mehta, P. D. (2018) · CRC Press eBooks · doi:10.1201/9781315376875-4

Aβ Variants and Their Impact on Amyloid Formation and Alzheimer’s Disease Progression

Ötvös, L. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_7

Demenz

Wiltfang, J., Trost, S., & Hampel, H.-J. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_59-1

Demenz

Hampel, H. J., & Pantel, J. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_47

Demenz

Hampel, H. J., Bürger, K., & Fuchsberger, T. (2006) · Springer eBooks · doi:10.1007/3-540-27386-7_41

The Early Diagnosis of Alzheimer's Disease

Ren, Y., Yang, W., Tang, X., Wu, F., Takahashi, S., & Wu, J. (2020) · IGI Global eBooks · doi:10.4018/978-1-7998-3441-0.ch008

Intensive protein synthesis in neurons and phosphorylation of beta-amyloid precursor protein and tau-protein are triggering factors of neuronal amyloidosis and Alzheimer’s disease

Maltsev, A. V., Dovidchenko, N. V., Uteshev, V. K., Sokolik, V. V., Shtang, O. M., Yakushin, M. A., Sokolova, N. M., Surin, A. K., & Galzitskaya, O. V. (2013) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750813040057

Mesenchymal Cell-Derived Extracellular Vesicles Ameliorate Age-Related Deficits in Working Memory as well as Brain MRI and CSF in vivo Biomarkers of Neurodegeneration in Rhesus MonkeysPreprint

Mackie, E. C., Cheng, C.-H., Alibrio, M. N., Rutledge, C., Xin, H., Chopp, M., McCann, R., Rosene, D. L., Yang, Q., Zeldich, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.14.623673

Clinical and neuropathologic assessment of severity in Huntington's disease

Myers, R. H., Vonsattel, J. P., Stevens, T. J., Cupples, L. A., Richardson, E. P., Martin, J. B., & Bird, E. D. (1988) · Neurology · doi:10.1212/wnl.38.3.341 · Cited by 217 · see citing works

EEG Frequency Analysis in Demented and Nondemented Parkinsonian Patients

Neufeld, M. Y., Blumen, S. C., Aitkin, I., Parmet, Y., & Korczyn, A. D. (1994) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000106690 · Cited by 108 · see citing works

Cerebrospinal fluid arginine vasopressin in Parkinson's disease, dementia, and other degenerative disorders.

Olsson, J. E., Forsling, M. L., Lindvall, B., et al. (1987) · PubMed · Cited by 7 · see citing works

Dementia in Parkinson's disease. Morphometric data.

Duyckaerts, C. J., Gaspar, P., Costa, C. C., et al. (1993) · PubMed · Cited by 32 · see citing works

Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls.

Peskind, E. R., Leverenz, J. B., Farlow, M. R., et al. (1997) · PubMed · Cited by 13 · see citing works